SEARCH:   Advanced

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Corbellino, M. Articles by Parravicini, C. Search for Related Content PubMed PubMed Citation Articles by Corbellino, M. Articles by Parravicini, C. Related Collections Neoplasia Brief Reports Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Blood, 1 December 2001, Vol. 98, No. 12, pp. 3473-3475 BRIEF REPORT Long-term remission of Kaposi sarcoma-associated herpesvirus-related multicentric Castleman disease with anti-CD20 monoclonal antibody therapy Mario Corbellino, Giovanna Bestetti, Chiara Scalamogna, Sara Calattini, Morena Galazzi, Luca Meroni, Daniele Manganaro, Marco Fasan, Mauro Moroni, Massimo Galli, and Carlo Parravicini From the Institute of Infectious Diseases and Tropical Medicine, University of Milan; and the First Division of Infectious Diseases and the Department of Pathology, Luigi Sacco Hospital, Milan, Italy. Kaposi sarcoma-associated herpesvirus (KSHV)-related multicentric Castleman disease (MCD) is potentially lethal. Growing evidence indicates that, as in Epstein-Barr virus-driven lymphoproliferative disorders after transplantation, KSHV DNA burden in peripheral blood mononuclear cells (PBMCs) may represent the most accurate marker of disease activity. This report describes a patient with human immunodeficiency virus who was followed up clinically and by quantitative polymerase chain reaction for KSHV DNA sequences in PBMCs for more than 3 years following the diagnosis of KSHV-related MCD. Therapy with the antiherpesvirus agent cidofovir, antihuman interleukin-6 antibody BE-8, antiblastic chemotherapy, and combination antiretroviral agents did not achieve durable clinical or virologic remission of the disease. By contrast, administration of the anti-CD20 monoclonal antibody rituximab was well tolerated and allowed a 14-month remission of clinical symptoms and KSHV viremia. Rituximab should be added to the therapeutic armamentarium for KSHV-related MCD. © 2001 by The American Society of Hematology.   CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: M. Bower, O. Veraitch, R. Szydlo, P. Charles, P. Kelleher, B. Gazzard, M. Nelson, and J. Stebbing Cytokine changes during rituximab therapy in HIV-associated multicentric Castleman disease Blood, May 7, 2009; 113(19): 4521 - 4524. [Abstract] [Full Text] [PDF] P. Gasperini, S. Sakakibara, and G. Tosato Contribution of viral and cellular cytokines to Kaposi's sarcoma-associated herpesvirus pathogenesis J. Leukoc. Biol., October 1, 2008; 84(4): 994 - 1000. [Abstract] [Full Text] [PDF] M. Bower, T. Powles, S. Williams, T. N. Davis, M. Atkins, S. Montoto, C. Orkin, A. Webb, M. Fisher, M. Nelson, et al. Brief Communication: Rituximab in HIV-Associated Multicentric Castleman Disease Ann Intern Med, December 18, 2007; 147(12): 836 - 839. [Abstract] [Full Text] [PDF] T. Powles, J. Stebbing, S. Montoto, M. Nelson, B. Gazzard, C. Orkin, A. Webb, and M. Bower Rituximab as retreatment for rituximab pretreated HIV-associated multicentric Castleman disease Blood, December 1, 2007; 110(12): 4132 - 4133. [Full Text] [PDF] L. Gerard, A. Berezne, L. Galicier, V. Meignin, M. Obadia, N. De Castro, C. Jacomet, R. Verdon, I. Madelaine-Chambrin, E. Boulanger, et al. Prospective Study of Rituximab in Chemotherapy-Dependent Human Immunodeficiency Virus Associated Multicentric Castleman's Disease: ANRS 117 CastlemaB Trial J. Clin. Oncol., August 1, 2007; 25(22): 3350 - 3356. [Abstract] [Full Text] [PDF] D. T. Scadden, V. V. Muse, and R. P. Hasserjian Case records of the Massachusetts General Hospital. Case 30-2006. A 41-year-old man with dyspnea, fever, and lymphadenopathy. N. Engl. J. Med., September 28, 2006; 355(13): 1358 - 1368. [Full Text] [PDF] W. H. Navarro and L. D. Kaplan AIDS-related lymphoproliferative disease Blood, January 1, 2006; 107(1): 13 - 20. [Abstract] [Full Text] [PDF] N. Nishimoto, Y. Kanakura, K. Aozasa, T. Johkoh, M. Nakamura, S. Nakano, N. Nakano, Y. Ikeda, T. Sasaki, K. Nishioka, et al. Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease Blood, October 15, 2005; 106(8): 2627 - 2632. [Abstract] [Full Text] [PDF] J. R. Brown and A. T. Skarin Clinical Mimics of Lymphoma Oncologist, July 1, 2004; 9(4): 406 - 416. [Abstract] [Full Text] [PDF] A. Berezne, F. Agbalika, E. Oksenhendler, C. Casper, W. G. Nichols, M.-L. Huang, L. Corey, and A. Wald Failure of cidofovir in HIV-associated multicentric Castleman disease Blood, June 1, 2004; 103(11): 4368 - 4369. [Full Text] [PDF] C. Casper, W. G. Nichols, M.-L. Huang, L. Corey, and A. Wald Remission of HHV-8 and HIV-associated multicentric Castleman disease with ganciclovir treatment Blood, March 1, 2004; 103(5): 1632 - 1634. [Abstract] [Full Text] [PDF] J. J. Goedert Multicentric Castleman disease: viral and cellular targets for intervention Blood, October 15, 2003; 102(8): 2710 - 2711. [Full Text] [PDF] A.-G. Marcelin, L. Aaron, C. Mateus, E. Gyan, I. Gorin, J.-P. Viard, V. Calvez, and N. Dupin Rituximab therapy for HIV-associated Castleman disease Blood, October 15, 2003; 102(8): 2786 - 2788. [Abstract] [Full Text] [PDF]

	Copyright © 2001 by American Society of Hematology         Online ISSN: 1528-0020